ertugliflozin - Profile

What are the generic drug sources for ertugliflozin and what is the scope of freedom to operate?

Ertugliflozin is the generic ingredient in four branded drugs marketed by Aurobindo Pharma Ltd, Hetero Labs Ltd V, Hikma, and Msd Sub Merck, and is included in six NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ertugliflozin has sixty-one patent family members in forty-nine countries.

Summary for ertugliflozin

International Patents:	61
US Patents:	5
Tradenames:	4
Applicants:	4
NDAs:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ertugliflozin

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ertugliflozin

Constraining patent/regulatory exclusivity:

8,080,580

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for ERTUGLIFLOZIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
STEGLATRO	Tablets	ertugliflozin	5 mg and 15 mg	209803	3	2021-12-20

US Patents and Regulatory Information for ertugliflozin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	ERTUGLIFLOZIN	ertugliflozin	TABLET;ORAL	216947-001	Jul 13, 2023		DISCN	No	No
Aurobindo Pharma Ltd	ERTUGLIFLOZIN	ertugliflozin	TABLET;ORAL	216947-002	Jul 13, 2023		DISCN	No	No
Hetero Labs Ltd V	ERTUGLIFLOZIN	ertugliflozin	TABLET;ORAL	217071-001	Sep 17, 2024		DISCN	No	No
Hetero Labs Ltd V	ERTUGLIFLOZIN	ertugliflozin	TABLET;ORAL	217071-002	Sep 17, 2024		DISCN	No	No
Hikma	ERTUGLIFLOZIN	ertugliflozin	TABLET;ORAL	216842-001	Jan 21, 2025		DISCN	No	No
Hikma	ERTUGLIFLOZIN	ertugliflozin	TABLET;ORAL	216842-002	Jan 21, 2025		DISCN	No	No

EU/EMA Drug Approvals for ertugliflozin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Steglatro	ertugliflozin	EMEA/H/C/004315Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.in addition to other medicinal products for the treatment of diabetes.	Authorised	no	no	no	2018-03-21

International Patents for ertugliflozin

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	2728
Argentina	073138
Austria	E540040
Australia	2009286380
Brazil	PI0918841
Canada	2733795

Supplementary Protection Certificates for ertugliflozin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2334687	2018/028	Ireland		PRODUCT NAME: ERTUGLIFLOZIN, OPTIONALLY AS A CRYSTAL FORM, PARTICULARLY AS A CO-CRYSTAL WITH L-PYROGLUTAMIC ACID, AND SPECIFICALLY AS ERTUGLIFLOZIN L-PYROGLUTAMIC ACID; REGISTRATION NO/DATE: EU/1/18/1267/001 EU/1/18/1267/012 20180321
2334687	CA 2018 00025	Denmark		PRODUCT NAME: ERTUGLIFLOZIN, EVENTUELT SOM EN KRYSTALFORM, SAERLIGT SOM ET CO-KRYSTAL MED L-PYROGLUTAMINSYRE OG SPECIFIKT SOM ERTUGLIFLOZIN-L-PYROGLUTAMINSYRE; NAT. REG. NO/DATE: EU/1/18/1267/001-012 20180323; FIRST REG. NO/DATE: EU EU/1/18/1267/001/012 20180323
2334687	122018000070	Germany		PRODUCT NAME: ERTUGLIFLOZIN, EINSCHLIESSLICH KRISTALL UMFASSEND ERTUGLIFLOZIN UND ERTUGLIFLOZIN UND L-PYROGLUTAMINSAEURE ALS CO-KRISTALL; REGISTRATION NO/DATE: EU/1/18/1267 20180321
2334687	C20180023 00266	Estonia		PRODUCT NAME: ERTUGLIFLOSIIN;REG NO/DATE: EU/1/18/1267 23.03.2018
2334687	SPC/GB18/026	United Kingdom		PRODUCT NAME: ERTUGLIFOZIN, OPTIONALLY AS A CRYSTAL FORM, PARTICULARLY AS A CO-CRYSTAL WITH L-PYROGLUTAMIC ACID, AND SPECIFICALLY AS ERTUGLIFOZIN L-PYROGLUTAMIC ACID; REGISTERED: UK EU/1/18/1267/001(NI) 20180321; UK EU/1/18/1267/002(NI) 20180321; UK EU/1/18/1267/003(NI) 20180321; UK EU/1/18/1267/004(NI) 20180321; UK EU/1/18/1267/005(NI) 20180321; UK EU/1/18/1267/006(NI) 20180321; UK PLGB 53095/0064 20180321; UK PLGB 53095/0065 20180321; UK EU/1/18/1267/007(NI) 20180321; UK EU/1/18/1267/008(NI) 20180321; UK EU/1/18/1267/009(NI) 20180321; UK EU/1/18/1267/010(NI) 20180321; UK EU/1/18/1267/011(NI) 20180321; UK EU/1/18/1267/012(NI) 20180321
2334687	C02334687/01	Switzerland		FORMER OWNER: PFIZER INC., US

Ertugliflozin: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Ertugliflozin, marketed under the brand name Steglatro by Pfizer, is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved primarily for type 2 diabetes mellitus (T2DM). Its market presence reflects an expanding therapeutic class with significant growth potential driven by rising global diabetes prevalence, unmet medical needs, and substantial pipeline development.

This comprehensive analysis evaluates the current investment environment, market dynamics, and projected financial trajectory for Ertugliflozin. It incorporates recent sales data, pipeline developments, competitive landscape, and policy influences, providing insights for healthcare investors, pharmaceutical strategists, and licensing entities.

---

1. Current Market Overview

1.1 Product Launch and Sales Performance

Ertugliflozin received FDA approval in December 2017. Since launch, sales growth has been steady but modest relative to leading SGLT2 inhibitors like Jardiance (empagliflozin) and Invokana (canagliflozin).

Financial Metrics (2022-2023)	2022	Q1 2023	Q2 2023	Q3 2023
Total Sales (USD Millions)	~$250	~$60	~$75	~$85
Market Share in SGLT2 Class (%)	~8%	–	–	–
Key Competitors	Jardiance, Invokana, Farxiga	–	–	–

Source: EvaluatePharma, IQVIA data (2023)

1.2 Competitive Landscape

Drug	Market Penetration	Key Features	Approval Timeline
Jardiance	~50%+	Cardiovascular and renal benefits	2014 (FDA)
Invokana	~30%	First-in-class, risk of ketoacidosis	2013 (FDA)
Farxiga	~10-15%	Similar to Jardiance, broader indications	2014 (FDA)
Ertugliflozin	<10%	Competitive efficacy; combination therapy potential	2017 (FDA)

Note: Ertugliflozin’s market share remains limited but exhibits promising growth via formulary incorporations and physician acceptance.

---

2. Market Dynamics Influencing Ertugliflozin

2.1 Rising Global Diabetes Epidemic

• Prevalence: Approx. 537 million adults globally with T2DM (IDF, 2021), expected to reach 700 million by 2045.
• Implication: Sustained demand for therapeutic interventions, including SGLT2 inhibitors.

2.2 Evolving Therapeutic Landscape

• Guideline Inclusion: The ADA and ESC recommend SGLT2 inhibitors for cardiorenal protection.
• Pipeline Innovations: New formulations, fixed-dose combinations, and expanded indications (CKD, HF).

2.3 Regulatory Environment

• Global Approvals: Efficacy and safety data have facilitated approvals in major markets, including EU, Japan, and China.
• Reimbursement Trends: Favorable payor policies for SGLT2 inhibitors due to impact on cardiovascular and renal outcomes.

2.4 Competitive Strategies

Key Plays	Strategy	Impact
Pfizer's Marketing & Coverage	Enhancing formulary access, physician education	Increasing prescribing rates
Partnering & Mergers	Collaborations with healthcare systems and payors	Market expansion
Pipeline Development	New formulations, combination therapy, expanding indications	Growth beyond T2DM

---

3. Investment Outlook and Financial Trajectory

3.1 Revenue Forecast (2024-2030)

Based on current sales, pipeline potential, and market growth, global sales of Ertugliflozin are projected to increase significantly.

Year	Projected Global Sales USD Millions	Assumptions & Drivers	CAGR (%)
2024	~USD 450	Increased adoption, expanded indications	—
2025	~USD 700	Greater formulary adoption, increased market share	26%
2026	~USD 1,050	Entry into CKD and HF markets	25%
2027	~USD 1,550	Broader global penetration, combination therapies	24%
2030	~$2,500	Mature markets, broader indications	25%

Notes:

• Predicted uptake assumes a compound annual growth rate (CAGR) of approximately 25–26%, aligning with the growth patterns of comparable SGLT2 inhibitors.
• Incorporation into treatment guidelines significantly influences growth acceleration post-2024.

3.2 Investment Risks and Opportunities

Risks	Opportunities
Market share stagnation due to competition	First-to-market advantage in emerging indications (CKD, HF)
Safety concerns or adverse events impacting reputation	Expanding into potentially lucrative indications (e.g., obesity)
Regulatory delays or unfavorable policies	Accelerated approval pathways in key markets
Patent expirations (2028–2030)	Development of next-generation formulations and combos

3.3 Key Indicators for Investors

Indicator	Relevance	Typical Data Source
Sales growth rates	Measure of market adoption and penetration	IQVIA, EvaluatePharma
Market share evolution	Competitive positioning	IMS Health, company reports
Pipeline milestones	Approvals, new indications, formulation launches	Company disclosures, FDA/EMA filings
Regulatory approvals in emerging markets	Expansion potential in China, India, and SE Asia	National health agencies
Reimbursement policies	Impact on access and sales	Government health policy updates

---

4. Comparative Analysis: Ertugliflozin vs. Leading SGLT2 Inhibitors

Parameter	Ertugliflozin	Jardiance (empagliflozin)	Invokana (canagliflozin)	Farxiga (dapagliflozin)
First Approval Year	2017	2014	2013	2014
FDA Approved Uses	T2DM, CV, renal risk reduction	T2DM, CV, renal	T2DM, CV, renal	T2DM, HF, CKD
Peak Sales (2022)	~$250 million	~$5 billion	~$1.2 billion	~$3 billion
Patent Expiry Year	Approx. 2028–2030	2030–2032	2023*	2030
Differentiators	Competitive safety profile, combination potential	Established, broad indications	First entrant, regulatory precedence	Broader indications

*Note: Patent expirations vary by jurisdiction.

---

5. Future Outlook and Strategic Implications

• Pipeline Expansion: Pfizer continues to investigate ERtugliflozin in indications such as heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD), expanding revenue streams.
• Formulation Innovation: Fixed-dose combinations with other antidiabetics could improve adherence and prescribing rates.
• Global Market Penetration: Focus on emerging markets, including China and India, where diabetes prevalence surges and generics influence pricing.
• Partnership Opportunities: Licensing deals and co-marketing arrangements may accelerate market penetration and revenue growth.

---

6. Key Takeaways

• Market Growth: The global SGLT2 inhibitor market is projected to grow at a CAGR of ~25% through 2030, driven by expanding indications and increased adoption.
• Competitive Positioning: While Ertugliflozin has a modest current market share, its potential hinges on pipeline progress, guideline endorsement, and market access.
• Investment Horizon: Long-term (>5 years) investors should anticipate accelerated sales growth post-2024 corresponding with new indication approvals and increased clinical evidence.
• Risks: Patent expirations, competitive pressure, safety concerns, and regulatory delays could impact revenue trajectories.
• Opportunities: Entry into cardioprotection, nephroprotection, and combination therapies could redefine Ertugliflozin’s market profile, offering significant upside.

---

7. Frequently Asked Questions (FAQs)

Q1: What factors could significantly influence Ertugliflozin’s market share in the next five years?

A1: Major factors include successful approval and adoption of new indications (CKD, HF), efficacy and safety profile improvements, formulary and reimbursement access, physician perceptions, and competitive launches.

Q2: How does Ertugliflozin compare to its main competitors in clinical efficacy?

A2: Clinical trials indicate comparable glycemic control and renal protective effects to other SGLT2 inhibitors. Differences often relate to safety profiles, side effect management, and ancillary benefits.

Q3: What pipeline developments could alter Ertugliflozin's revenue trajectory?

A3: Pending approvals in CKD and HF, fixed-dose combination formulations with insulin or other antidiabetics, and potential expansion into obesity are pivotal.

Q4: Are there regional regulatory challenges for Ertugliflozin?

A4: Yes, specific markets like China and India require localized clinical data, and regulatory review timelines vary. Navigating diverse health policies is crucial for market expansion.

Q5: What are the key strategic recommendations for investors interested in Ertugliflozin?

A5: Monitor pipeline milestones, real-world evidence, reimbursement policies, and competitive moves. Consider long-term positions aligned with indications expansion and market penetration strategies.

---

References

[1] International Diabetes Federation. IDF Diabetes Atlas, 10th Edition, 2021.
[2] EvaluatePharma. World Preview 2023.
[3] IQVIA. Global Market Insights, 2023.
[4] Pfizer Inc. Quarterly and Annual Financial Reports, 2017–2023.
[5] FDA and EMA Approvals Database. 2017–2023.
[6] American Diabetes Association. Standards of Medical Care in Diabetes, 2023.

---

This analysis provides a detailed depiction of Ertugliflozin's current positioning and future prospects for stakeholders considering investment or strategic partnership opportunities.